Biostar Stem Cell Research Institute Decides to Register Patent for ‘Separating∙Culturing Technology of Amniotic Epithelial Stem Cells’ in Europe

• 6^th patent registered in Europe followed after Korea, Mexico, Canada, the U.S., Japan.
• Cell therapy efficacy promoting patent for ‘Technology for Composition of Intravenously Injected Stem Cells’ also registered in Korea

Biostar Stem Cell Research Institute, joint-operated by Nature Cell and R Bio, announced on the 14^th that they have been informed by Europe about the registration decision of the patent for ‘Separating Culturing Method of Human amniotic epithelial stem cell-derived-adult stem cells’(Europe patent no.: 08704712.2)

This patent is differentiated from others from the fact that the technique of easily separating and culturing epithelial stem cells from placental amnion makes it easier to collect stem cells than that of cord blood or bone marrow, and also increase the reproduction rate. When applied on future treatments, it is expected to enhance efficacy.

Amniotic epithelial stem cells play a pivotal role in the fetus protecting placenta, and can be easily collected during birth. It is now in the limelight of treating incurable diseases, for it is ethical and non-carcinogenic, and acts as pluripotent stem cells.

Biostar Stem Cell Research Institute reported that they have been recently notified that the patent ‘composition of intravenously injected stem cells’ (domestic patent no.: 10-2013-0055158) has been decided to be registered.

In particular, the component of the stem cells are made in diameter of 10~20㎛ so that they do not get destroyed or coagulated before injected intravenously and reach the target site.

Accordingly, because treatment through injected stem cells can improve the treatment effects, treating illnesses, such as Parkinson’s disease, in which it is difficult to give indirect injection, is anticipated. The patent application is submitted not only within Korea, but also in the states, Japan, Europe, and China.

“Through the decision on domestic patent registration, the importance of the technique to effectively and safely culture stem cells in order to inject intravenously has been acknowledged. Also, this will help in business of regenerative medicine, joint carried by Nature Cell,” said Jeong-Chan Ra, the director of Biostar SCRI